The FDA has approved an early feasibility study of Retina Implant’s Alpha AMS subretinal device in blind patients with retinitis pigmentosa, Wills Eye Hospital announced in a press release.
Wills Eye Hospital, the sole sponsor of the study in North America, will enroll up to eight subjects for implantation of the investigational device, the release said. The Alpha AMS device, which is CE marked in Europe, is designed to replace the eye’s nonfunctioning and absent photoreceptors and to restore some functional vision by stimulating the remaining parts of the visual (Read more...)
Uncategorized